Collaborative COVID-19 lockdown effort delivers major boost for vaccine innovation in Bristol

Faster vaccine development could be a step closer thanks to £ 4 million investment to Imophoron Ltd, a Bristol University biotech start-up developing a novel, next generation rapid-response vaccine platform called ADDomer ™ . Imophoron will use the investment to bring ADDomer vaccines to clinical stage, initially targeting three viruses, RSV (respiratory syncytial virus), COVID-19, and mosquito-borne Chikungunya.
Source: University of Bristol news - Category: Universities & Medical Training Tags: Announcements, Business and Enterprise, Grants and Awards, Health, International, Research; Faculty of Health Sciences, Faculty of Health Sciences, Bristol Medical School, Faculty of Life Sciences, Faculty of Life Sciences, School of Biochemistry, Faculty Source Type: news